Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadaaki Yamada

Showing results (61-70 of 228) with videos related to

Pageof 23
Sort By:
Molecular Cancer Therapeutics|October 29, 2017
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring <i>RAS</i> MutationsTadaaki Yamada, Joseph M Amann, Azusa Tanimoto, et al.
International Journal of Cancer|September 18, 2015
Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancerShinji Takeuchi, Koji Fukuda, Sachiko Arai, et al.
Cancer Science|August 30, 2008
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2Tadaaki Yamada, Seiji Yano, Hirokazu Ogino, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2012
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisHitomi Koizumi, Tadaaki Yamada, Shinji Takeuchi, et al.
Thoracic Cancer|January 24, 2019
Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasisAkihiro Yoshimura, Tadaaki Yamada, Taisuke Tsuji, et al.
Cancer Science|September 8, 2011
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cellsTadaaki Yamada, Hideaki Bando, Shinji Takeuchi, et al.
Internal Medicine (Tokyo, Japan)|September 17, 2009
Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsyKoushiro Ohtsubo, Hiroyuki Watanabe, Tadaaki Yamada, et al.
Cancer Science|October 27, 2016
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitorsHirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, et al.
Translational Lung Cancer Research|August 2, 2019
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancerAkihiro Yoshimura, Junji Uchino, Koichi Hasegawa, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 23, 2005
[A case of sarcoidosis with diffuse pulmonary arteriovenous malformations]Hiroomi Kuwahara, Tadaaki Yamada, Tatsuya Yuba, et al.
Pageof 23

Showing results (61-70 of 228) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|October 29, 2017
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring <i>RAS</i> MutationsTadaaki Yamada, Joseph M Amann, Azusa Tanimoto, et al.
International Journal of Cancer|September 18, 2015
Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancerShinji Takeuchi, Koji Fukuda, Sachiko Arai, et al.
Cancer Science|August 30, 2008
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2Tadaaki Yamada, Seiji Yano, Hirokazu Ogino, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2012
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisHitomi Koizumi, Tadaaki Yamada, Shinji Takeuchi, et al.
Thoracic Cancer|January 24, 2019
Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasisAkihiro Yoshimura, Tadaaki Yamada, Taisuke Tsuji, et al.
Cancer Science|September 8, 2011
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cellsTadaaki Yamada, Hideaki Bando, Shinji Takeuchi, et al.
Internal Medicine (Tokyo, Japan)|September 17, 2009
Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsyKoushiro Ohtsubo, Hiroyuki Watanabe, Tadaaki Yamada, et al.
Cancer Science|October 27, 2016
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitorsHirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, et al.
Translational Lung Cancer Research|August 2, 2019
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancerAkihiro Yoshimura, Junji Uchino, Koichi Hasegawa, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 23, 2005
[A case of sarcoidosis with diffuse pulmonary arteriovenous malformations]Hiroomi Kuwahara, Tadaaki Yamada, Tatsuya Yuba, et al.
Pageof 23